Hellman Jordan Management Company’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-6,708
Closed -$675K 77
2021
Q3
$675K Buy
6,708
+2,190
+48% +$257K 0.95% 41
2021
Q2
$639K Sell
4,518
-116
-3% -$13.1K 1.14% 36
2021
Q1
$462K Buy
+4,634
New +$540K 0.67% 50

Other funds holding RETA

Hellman Jordan Management Company's RETA Position: Q4 2021 in Review

Hellman Jordan Management Company sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 6,708 shares — an estimated $675K sold.

Hellman Jordan Management Company first reported a position in RETA in Q1 2021 and held it in 3 quarters. The position peaked at $675K in Q3 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

  • Hellman Jordan Management Company reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Hellman Jordan Management Company sold 6,708 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $675K.
  • Hellman Jordan Management Company first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 3 quarters.
  • Hellman Jordan Management Company's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $675K in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Hellman Jordan Management Company's 13F filing for Q4 2021, filed 26 Jan 2022.